10x Genomics, Inc.

Company focus

• Life sciences technology company focused on accelerating mastery of biology to advance human health.
• Builds integrated research solutions to interrogate, understand, and master biology at high resolution and scale.
• Portfolios include instruments, consumables, and software across single-cell, spatial, and in situ capabilities, with multiomic readouts (gene expression, proteins, chromatin, V(D)J, CRISPR/gRNA, antigens).

Core platforms and products

• Single-cell portfolio (Chromium family)
  • Microfluidic chips and related consumables; Chromium X Series and legacy Chromium instruments.
  • Capabilities include partitioning and barcoding of greater than 1 million components per partition; supports multiomic readouts.
• Spatial portfolio
  • Visium platform (spatial transcriptomics) with high-density DNA arrays encoding spatial location; paired with imaging (H&E/IR) data.
  • Xenium platform for in situ analysis to map hundreds of RNA targets directly in tissue sections without sequencing.
• Software
  • Cell Ranger (scRNA-seq processing), Loupe Browser (visualization for single-cell/spatial/multiomic data), Xenium Explorer (in situ data visualization).
• Additional kits
  • QuantumScale Single Cell RNA and Single Cell Methylation kits (acquired via Scale Biosciences in 2025).

Market and customers

• Primary customers: academic and government researchers, biopharmaceutical and biotechnology companies, and other life-sciences research institutions.
• Global footprint: products sold in over 50 countries; direct sales in North America and parts of Europe; third-party distributors in Asia, Europe, Oceania, North America, South America, the Middle East, and Africa.
• No single customer (including distributors) accounted for more than 10% of revenue in 2025 or 2024.
• More than 10,000 peer-reviewed articles have been published based on data from company products to date.

Key performance indicators (year ended December 31, 2025)

• Revenue: $642.8 million in 2025; $610.8 million in 2024 (up 5% year over year).
• Net (loss) income: $(43.5) million in 2025; $(182.6) million in 2024.
• Instruments sold: 1,007 in 2025; 1,073 in 2024.
• Consumable reactions sold: 424,000 in 2025; 357,100 in 2024.
• Total instruments sold since inception (mid-2015 through 12/31/2025): 8,046.
• Employees: 1,178 total as of 12/31/2025
  • U.S. employees: 822; International employees: 356.
  • By function: R&D 332; Sales/Marketing/Support 473; General & Administrative 185; Manufacturing 188.
• Corporate structure: multi-class common stock (Class A and Class B) with concentrated voting control by co-founders; governance provisions typical of a public technology/biotechnology company.

Growth and strategy

• Resolution and scale: tools designed to measure biology at single-cell or high-spatial-resolution levels while enabling millions of measurements per experiment.
• Platform integration: expand the ecosystem through software integrations and strategic partnerships to broaden access to data analysis and accelerate translation to research and clinical use.
• Market opportunity: estimates position the total addressable market of the broader life sciences research tools sector at about $75 billion, with a reported addressable market greater than $21 billion and a serviceable addressable market greater than $13 billion under various adoption scenarios.

Regulatory and product-use context

• Many products are marketed for research use only (RUO); use of an RUO product for diagnostic purposes can have regulatory implications.
• Global operations expose the company to diverse regulatory regimes (FDA and EU/UK frameworks for IVDs/diagnostics, CLIA-related considerations for clinical use), with corresponding regulatory risks reflected in public disclosures.

This summary describes 10x Genomics’ business focus, core products and platforms, market presence, financial and operational metrics, and strategic priorities based on the provided information.